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Several lines of evidence suggest that lipid rafts are involved in cellular fatty acid uptake and influence fatty acid translocase (FAT/CD36)
function. However, it remains unknown whether caveolae, a specialized raft type, are required for this mechanism. Here, we show that wild-type
(WT) mouse embryonic fibroblasts (MEFs) and caveolin-1 knockout (KO) MEFs, which are devoid of caveolae, have comparable overall
expression of FAT/CD36 protein but altered subcellular FAT/CD36 localization and function. In WT MEFs, FAT/CD36 was isolated with both
lipid raft enriched detergent-resistant membranes (DRMs) and detergent-soluble membranes (DSMs), whereas in cav-1 KO cells it was exclusively
associated with DSMs. Subcellular fractionation demonstrated that FAT/CD36 in WT MEFs was localized intracellularly and at the plasma
membrane level while in cav-1 KO MEFs it was absent from the plasma membrane. This mistargeting of FAT/CD36 in cav-1 KO cells resulted in
reduced fatty acid uptake compared to WT controls. Adenoviral expression of caveolin-1 in KO MEFs induced caveolae formation, redirection of
FAT/CD36 to the plasma membrane and rescue of fatty acid uptake. In conclusion, our data provide evidence that caveolin-1 is necessary to target
FAT/CD36 to the plasma membrane. Caveolin-1 may influence fatty acid uptake by regulating surface availability of FAT/CD36.
© 2006 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords: Lipid raft; Caveolin-1; Caveolae; Fatty acid translocase1. Introduction
Uptake of long-chain fatty acids (LCFAs) is essential for
many cellular functions and is achieved by a concert of co-
existing mechanisms that probably varies in different cell
types. In adipocytes, permeation of LCFAs across the plasma
membrane relies on a high affinity, low capacity carrier-
facilitated transport system [1]. The important role of fatty
acid translocase (FAT/CD36) for LCFA uptake in adipocytes
has been extensively studied. When overexpressed in cultured
fibroblasts FAT/CD36 increases saturable, high-affinity LCFA
uptake [2]. Moreover, FAT/CD36 knockout mice have
increased serum fasting levels of nonesterified free fatty
acids and reveal reduced uptake of oleate in isolated⁎ Corresponding author. Tel.: +49 6221 568703; fax: +49 6221 564116.
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Open access under CC BY-NC-ND license.adipocytes [3]. Recently, we showed that in 3T3-L1
adipocytes, plasma membrane FAT/CD36 is located within
detergent-resistant membranes (DRMs), which are enriched in
lipid rafts components, whereas intracellular FAT/CD36
cofractionated with detergent-soluble membranes (DSMs)
[4]. Indeed, evidence is accumulating that lipid rafts play a
crucial role in regulating LCFA uptake [4–7]. Rafts are
dynamic assemblies of sphingolipids and cholesterol that con-
tain a select set of membrane proteins (reviewed in [8]). Caveolae
represent a morphologically identifiable subset of lipid rafts that
are particularly abundant in adipocytes [9]. Their coat protein
caveolin-1 is essential for the formation of the characteristic flask-
shaped invaginations of the plasma membrane through a largely
unknown process [10,11]. Although the physiological roles of
caveolae remains uncertain, they have been suggested to parti-
cipate in a large number of important cellular functions including
the regulation of cellular cholesterol homeostasis [12,13] and
signal transduction (reviewed in [14]). Recently, several reports
suggested that caveolin-1 might be involved in lipid homeostasis
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major plasma membrane fatty-acid binding protein in adipocytes
[15]. Furthermore, caveolin-1 has been shown to move from the
plasma membrane to lipid droplets in response to free fatty acids
[16–18]. A role for caveolin-1 in trafficking of lipids was also
supported by reports on the phenotype of caveolin-1-deficient
mice [7,19]. Depletion of caveolin-1 or deletion of the caveolin-1
gene resulted in a complete loss of caveolae and significant white
adipose tissue atrophy with age. In addition, these mice have a
lean phenotype and show severely elevated serum levels of free
fatty acids and triglycerides, especially in the postprandial state
[7].
The possible role of lipid rafts in lipid flux has generated
considerable interest and activity in elucidating the protein
composition of these microdomains. While the overall bio-
chemical composition of caveolae and non-caveolar lipid rafts
is thought to overlap, these microdomains are not completely
equivalent. In addition to the caveolins, several other proteins
have been shown to preferentially localize to either caveolae or
non-caveolar lipid rafts [20]. Based on its partitioning into
DRM fractions, FAT/CD36 was suggested to associate with
lipid raft microdomains [4,5,21], but it remains to be determined
whether it is in caveolae.
In the present study, we used wild-type and caveolin-1 knock-
outmouse embryonic fibroblasts (cav-1 KO MEFs) as a model to
define the precise localization and regulation of FAT/CD36. We
found that FAT/CD36 function relies on caveolin-1 expression.
Deficiency of caveolin-1 resulted in a complete loss of caveolae,
absence of FAT/CD36 plasma membrane expression and reduction
of fatty acid uptake. Adenoviral expression of caveolin-1 in cav-1
KO MEFs induced re-formation of caveolae, targeting of FAT/
CD36 to the plasmamembrane and rescue of fatty acid uptake. It is
conceivable that the lack of FAT/CD36 stabilization at the plasma
membrane might contribute to the metabolic phenotype of the cav-
1 null mice.
2. Materials and methods
2.1. Reagents and antibodies
[3H]Oleic acid was purchased from Biotrend (Cologne, Germany). Fatty
acid free BSA (fraction V), dexamethasone, phloretin, EGTA, protease
inhibitors sucrose, EDTA, chymostatin, HOSu(SO3)Na, dicyclohexylcarbodii-
mide, N,N-dimethylformamide (DMF) and non-radio-labeled oleic acid were
purchased from Sigma Chemical Co. (St. Louis, MO). Ultima-Gold scintillation
fluid was purchased from Packard (Groningen, The Netherlands). DMSO was
from Merck (Darmstadt/ Germany). Tr3-Isobutyl-1-methylxanthin was from
Calbiochem (Bad Soden, Germany).
Antibodies and their sources were as follows: anti-caveolin-1 and anti-flotillin
(BD Transduction laboratories), anti-Na,K-ATPase and anti-calreticulin (Novus
Biological), anti-transferrin (Zymed Laboratories), anti-gp27/gp26 (kind gift of
Dr. M. Dominguez, Department of Anatomy and Cell Biology, McGill University,
Montreal, Canada).
Primary polyclonal antibodies against mouse FAT/CD36 were generated
using the synthetic peptide SYKGKRNLSYWPSYC to which a cysteine
residue had been added before coupling to keyhole limpet hemocyanin. The
antiserum was produced by injection of guinea pigs (Peptide Specialty
Laboratories, Heidelberg, Germany) and specifically detects FAT/CD36
protein [4]. Preincubation of the antiserum with the synthetic peptide ablated
reaction of the antiserum with FAT/CD36 by western blotting andimmunofluorescence, and pre-immune serum did not show any reactivity in
these assays.
2.2. Animals and tissues
Cav-1 KO mice were described previously [10]. Mice homozygously null
for the caveolin-1 gene were compared to wild type littermates at the age of
3 months. Mice were sacrificed by cervical dislocation and inguinal adipose
tissues were rapidly excised. All animal experiments were approved by local
authorities in accordance with criteria outlined by the American Physiological
Society.
2.3. Cell culture
Mouse embryonic fibroblasts (MEFs) were prepared from 13.5 p.c. embryos
obtained by homozygous crossings of cav-1KOmice orWTmice [10].MEFswere
immortalized according to the 3T3 protocol by passaging them continuously until
growth rates in culture resumed the rapid rates seen in early passage MEFs. MEFs
were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% (v/v) fetal bovine serum (FCS, Gibco BRL), 2 mM L-glutamine,
100 units/L penicillin, and 100 μg/L streptomycin at 37 °C in 10% CO2.
2.4. Synthesis of and treatment with sulfosuccinimidyl-oleate (SSO)
The synthesis of sulfosuccinimidyl derivatives of oleate (SSO) was
performed as described by Harmon et al. [22]. SSO treatment of differentiated
MEFs was applied using a modified protocol of Abumrad and coworkers [23].
Briefly, MEF monolayers in 5 cm Ø culture dishes were washed three times with
KRH buffer containing 0.2% fatty acid-free bovine serum albumin and glucose
(2 mM) and then incubated with 400 μmol SSO for 30 min at 37 °C. To avoid
toxicity of DMSO, the concentration of DMSO was always kept below 0.05%.
At the end of the incubation, MEFs were washed three times with KRH buffer
containing 0.2% fatty acid-free BSA in order to remove any unbound
sulfosuccinimidyl-oleate. Afterwards, cells were resuspended for assay of
oleate transport.
2.5. Assay for [3H]oleic acid uptake
The [3H]oleic acid uptake assays were performed as described previously
[24] using confluent MEFs. Briefly, trace amounts of [3H]oleic acid mixed with
173 μmol/L non-radioactive oleic acid were dissolved in a defatted BSA
solution (173 μmol/L) at a ratio of 1:1. Two mL of the oleate/BSA solution were
incubated with each MEF monolayer in a 5 cm Ø culture dish at 37 °C for 20 s.
The uptake was stopped by removal of the solution followed by addition of 5 mL
of an ice-cold stop solution containing 0.5% (w/v) albumin and 200 μM
phloretin. The stop solution was discharged after 2 min, and the culture dishes
were washed by dipping them six times in ice-cold incubation buffer. NaOH
(2 mol/L) was added to lyse the cells, and aliquots of the lysate were used for
protein and radioactivity determination. Radioactivity was determined after the
addition of 10 mL of Ultima-Gold in a 1217 Rackbeta liquid scintillation counter
(LKB-Wallac, Turku, Finland).
2.6. Isolation of detergent-resistant membranes
Detergent extraction with Triton X-100 was performed as described
previously [25]. MEFs were rinsed with ice-cold PBS and scraped on ice into
300 μL of 1% Triton X-100, 25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 3 mM
EDTA (TNE) buffer containing leupeptin, pepstatin, chymostatin, and antipain
(each at 25 μg/mL). Cells were homogenized 15 times through a 22 gauge
needle followed by 10 strokes with a tight fitting Dounce homogenizer. The
lysate was centrifuged for 5 min at 3000 rpm to obtain a postnuclear supernatant.
The supernatant was adjusted to 40% sucrose and overlaid with a discontinuous
sucrose gradient (6 mL of 30% sucrose in TNE or 2 mL of TNE without
sucrose). The gradients were centrifuged at 200,000 × g in a Beckman SW41
rotor for 16–22 h at 4 °C. Fractions (1 mL each) were obtained and used for
liquid scintillation counting and Western blotting.
Fig. 1. FAT/CD36 expression in inguinal adipose tissues andMEFs derived from
WT and Cav-1 KO mice. (A) Expression of caveolin-1 and FAT/CD36 in
inguinal adipose tissues from WT and cav-1 KO mice. For western blotting,
20 μg of total lysate was loaded per lane. FAT/CD36 mRNA expression was
assessed by real time PCR as described in Materials and methods. The
expression was normalized against expression of GAPDH. As expected,
caveolin-1 was not detected in adipose tissues from cav-1 KO mice. No
significant changes were observed between FAT/CD36 expression at either the
protein or mRNA levels. (B) Expression of caveolin-1 and FAT/CD36 in MEFs
derived from embryos from WT and cav-1 KO mice. A total of 50 μg of protein
was applied per lane. As expected, caveolin-1 expression was ablated in the cav-
1 KOMEFs. Expression of FAT/CD36 at either the protein or mRNA levels was
comparable in WT and cav-1 KO MEFs.
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gradient
Fractionation of the membranes was performed using the OptiPrep gradient by
AXIS-Shield (AXIS-Shield, Oslo, Norway) according to the instructions of the
manufacturer. Briefly, cells were washed once with PBS to remove the culture
medium and then resuspended in homogenization buffer (sucrose 25 mM, EDTA
0.5 mM, Tris 10 mM). Afterwards, cells were scraped in 3 mL homogenization
buffer and centrifuged at 1000×g for 5 min. The pellet was resolved in 2 mL
homogenization buffer and cells were lysed by 10 passages through a fine syringe
needle followed by treatment with a tight-fitting Dounce homogenizer. The
homogenate was centrifuged at 1000×g for 10 min to obtain a postnuclear super-
natant. The supernatant was centrifuged at 100,000×g for 40 min and resuspended
in 1 mL homogenization buffer containing 25% (w/v) iodixanol. The cell suspen-
sion was loaded on a nine-step OptiPrep gradient consisting of 25, 22, 19, 16, 13,
10, 7, 4, 1% (w/v) iodixanol solutions. Centrifugation was done in Beckman SW
41Ti rotor at 200,000×g for 3 h at 4 °C. Eighteen fractions were collected from the
bottom of each centrifuge tube. A quarter of each fraction was analyzed with SDS-
PAGE and Western blotting.
2.8. Adenoviral infection
The adenovirus encoding caveolin-1 taggedwith fused EGFP in its C-terminus
was constructed according to He et al. [26]. cDNA of caveolin-1 GFP [27] was
subcloned into the shuttle vector pAd Track-CMV using BglII-Not I sites. The
adenoviral vectors were propagated in HEK 293 cells, purified on Optiprep
gradients and stored at −80 °C.
Incubation of MEFs with the adenovirus in serum-free medium for 4 h at 37 °C
followed by growth in standard medium for 2 days resulted in a 70–80% rate of
infection (as judged by GFP fluorescence). Afterwards, cells were processed for
membrane fractionation. YFP-GL-GPI adenovirus was used for mock infection
[27].
2.9. RNA preparation and Real-time quantitative RT-PCR
RNA isolation, cDNA synthesis, and quantitative RT-PCR were done as
described [28]. The levels of GAPDHmRNAwas used as an internal standard to
determine relative mRNA levels of the target genes in WTand cav-1 KO adipose




and for GAPDH 5′CAAGGTCATCCATGACAACTTTG3′ and 5′GGCCATCCA-
CAGTCTTCTGG3′.
2.10. Western blot analysis
Aliquots of membrane fractions or total lysate from inguinal adipose tissues
were separated with SDS-PAGE and transferred to nitrocellulose membranes.
Antibody binding was visualized using the ECL reagents (Amersham). Immu-
noreactive bands on autoradiography films were scanned (Epson GT 9600;
Epson, Tokyo, Japan) and quantified using Raytest image software (Raytest,
Straubenhardt, Germany).
2.11. Immunocytochemistry
MEFs were washed 3 times in PBS and fixed in 2% paraformaldehyde. The
antiserum against FAT/CD36 described above was applied for 4 h at a dilution of
1:50 at 4 °C followed by washing 3 times with 0.05 mmol/L Tris–HCl, pH 7.4.
The monoclonal antibody against caveolin-1 was from BD Transduction Labo-
ratories (Heidelberg, Germany) and used at a dilution of 1:100 overnight. The
secondary Cy2-conjugated antibodies against mouse and guinea pig (Dianova,
Hamburg, Germany) were applied for 2 h at 4 °C diluted 1:200 in 0.05 mmol/L
Tris–HCl, pH 7.4.
2.12. Electron microscopy
MEFs were grown on sapphire coverslips and rapidly frozen in 20% BSA in
medium using an EMPACT2 (Leica Microsystems) containing a rapid transfersystem (RTS) to facilitate loading and freezing. The frozen samples were freeze
substituted in aceton containing 1% osmium tetra-oxide and 0.1 uranyl acetate
using an AFS (Leica Microsystems) and afterwards embedded in Epon.
Ultrathin sections were counterstained according to standard procedures.
2.13. Statistical analysis
Results are given as means±S.D. of at least five observations. Student's
t-test was used to test for significant differences between means.
3. Results
3.1. Effect of caveolin-1 deficiency on FAT/CD36 expression
In order to determine if caveolin-1 influences FAT/CD36
mRNA levels or protein stabilization, we first studied FAT/
CD36 expression in inguinal adipose tissues fromWTand cav-1
KO mice. Fig. 1A shows that there was no difference between
FAT/CD36 protein expression and mRNA levels in WT and
cav-1 KO adipose tissues. Next, we analyzed FAT/CD36 in
MEFs isolated from WT or cav-1 KO embryos and found that
the FAT/CD36 protein and mRNA content in whole cell lysates
was comparable (Fig. 1B). From these data, we conclude that
caveolin-1 neither affects FAT/CD36 mRNA levels nor FAT/
CD36 protein stability.
In addition, the quantitative mRNA expression of FAT/CD36
in inguinal adipose tissue and MEFs ranged in the same order of
419A. Ring et al. / Biochimica et Biophysica Acta 1761 (2006) 416–423magnitude, suggesting that MEFs are a suitable cell culture
system to study FAT/CD36 localization and function.
3.2. FAT/CD36 is absent from lipid raft-enriched membrane
fractions in cav-1 KO MEFs
FAT/CD36 has been shown to associate with detergent-re-
sistant membranes (DRMs), which are enriched in lipid rafts
components. To investigate if caveolin-1 influences FAT/CD36
partitioning in DRM fractions, total lysates of WT and cav-1 KO
MEFs were extracted by Triton X-100 and floated on sucrose
gradients. Afterwards, fractions collected from the gradient were
analyzed by immunoblotting. Flotillin and caveolin-1 were used
as marker proteins for DRM fractions and the transferrin receptor
served as a marker for detergent-soluble membrane (DSM) frac-
tions (Fig. 2). In WT MEFs, FAT/CD36 was expressed in both
DRM and DSM fractions. In contrast, analysis of fractions from
cav-1 KO MEFs revealed that FAT/CD36 was present in DSMs
but completely absent from DRMs. A similar amount of total
protein was recovered from DRM and DSM fractions inWT (1.1±
0.09 mg and 4.6±1.2 mg, respectively) and cav-1 KO MEFs
(1.1±0.8 mg and 3.9±0.6 mg, respectively) showing that the
disappearance of FAT/CD36 from the DRM fractions in cav-1
KOMEFs was not due to a lower overall recovery of proteins in
these cells.
3.3. Caveolin-1 is required for stabilization of FAT/CD36 at the
plasma membrane
These findings indicated that caveolin-1 might be required as
an anchor for FAT/CD36 in DRMs. As plasma membrane FAT/Fig. 2. Expression of FAT/CD36 in lipid raft-enriched membrane fractions. WT
MEFs and cav1 KO MEFs were lysed in cold 1% Triton X-100, and the total
lysate was resolved on a sucrose density gradient by ultracentrifugation.
Fractions 1–12 (fraction 12 representing the top of the gradient) were collected,
separated by SDS-PAGE, and blotted with antibodies to caveolin-1 and flotillin
(marker proteins of DRMs), the transferrin receptor (marker protein of DSMs)
and FAT/CD36. While in WT MEFs, (A) FAT/CD36 was present in both DRMs
and DSMs, in cav-1 KO MEFs (B) it was excluded from DRMs.CD36 in 3T3-L1 adipocytes had previously been shown to be
located exclusively in DRMs [4], we hypothesized that in the
absence of caveolin-1 FAT/CD36 might be retained intracellu-
larly and not be expressed on the plasma membrane at all. To
further test this hypothesis, we performed immunofluorescence
microscopy to examine the localization of FAT/CD36 in WT
and cav-1 KO MEFs. Fig. 3 shows that in WT MEFs, FAT/
CD36 is mainly located at the plasma membrane along the cell–
cell contact sites whereas in cav-1 KO cells it is exclusively
found in the cytoplasm. To corroborate this finding, we frac-
tionated WT and cav-1 KO MEFs homogenates on a discon-
tinuous iodixanol OptiPrep step gradient in order to separate
fractions containing plasma membrane (nos. 3–7), Golgi-net-
work (nos. 8–14) and endoplasmic reticulum (nos. 14–18)
(Fig. 4A). Na-K-ATPase, gp26/27 and calreticulin, respectively,
served as markers of these fractions. In WT MEFs, FAT/CD36
was present in the plasma membrane and Golgi fractions (Fig.
4B). In contrast, in cav-1 KOMEFs FAT/CD36 was absent from
plasma membrane fractions but was found in an intracellular
pool within the Golgi network fractions.
To investigate if expression of recombinant caveolin-1 is
sufficient for FAT/CD36 targeting to the plasma membrane, we
used a cav1-GFP adenovirus to restore caveolin-1 expression in
cav-1 KO MEFs. 48 h after infection, ∼70% of cells expressed
GFP (data not shown) and the amount of recombinant caveolin-1
expressed in cav-1 KO MEFs (rCav-1) was comparable to the
endogenous level in WTMEFs (Fig. 5A). Adenoviral expression
of caveolin-1-GFP in cav-1 KO cells was sufficient to induce
caveolae formation as shown by electron microscopy (Fig. 5B).
Membrane fractionation revealed that expression of recombinant
caveolin-1 in cav-1 KO MEFs shifted the cellular distribution of
FAT/CD36 from the Golgi compartment to the plasma membrane
(Fig. 5C). As a negative control for this experiment, cav-1 KO
cells were infected with a control adenovirus encoding YFP-GL-
GPI (YFP-tagged glycosylated form of glycosyl phosphatidyl
inositol anchor), known to associate with DRMs. Importantly,
this mock infection did not redirect FAT/CD36 to the plasma
membrane (Fig. 5C).
3.4. Fatty acid uptake parallels FAT/CD36 plasma membrane
expression
Since FAT/CD36 is known to play a major role in LCFA
incorporation, we next analyzed the effect of FAT/CD36 mis-
localization in cav-1 KO MEFs on fatty acid uptake. We found
that uptake of [3H]-oleic acid bound to albumin (173 μmol/L)
over 20 s was reduced by 61.6% in cav-1 KO compared to
WT MEFs (Fig. 6). Pretreatment with SSO, a selective
inhibitor of FAT/CD36 function, inhibited [3H]-oleate uptake
in WT MEFs by 41.1% but did not affect oleate uptake in cav-
1 KO MEFs. Re-expression of caveolin-1 in cav-1 KO cells
rescued fatty acid uptake nearly to levels of WT MEFs. In
rCav-1 cells, pretreatment with SSO inhibited oleate uptake by
almost 40%, although this effect did not reach statistical
significance (P=0.07). These findings show that the contri-
bution of FAT/CD36 to oleate uptake is abrogated in the
absence of caveolin-1.
Fig. 3. Immunofluorescence staining of FAT/CD36 and caveolin-1 in WTand cav-1 KOMEFs. In wild type MEFs, FAT/CD36 (A) and caveolin-1 (B) antibodies stain
the plasma membranes along the cell-cell borders. In contrast, CD36 is found exclusively in the cytosolic compartment of cav-1 KO MEFs and does not stain the
plasma membrane (C). Panel D shows the absence of caveolin-1 staining in the cav-1 KO MEFs.
Fig. 4. FAT/CD36 is absent from plasma membranes in cav-1 KO MEFs.
Fractionation was performed using a discontinuous OptiPrep step gradient, and
equal amounts of protein were separated by SDS-PAGE, blotted, and probed
with antibodies against the indicated protein. The detection of marker proteins
for plasma membrane (anti Na-K ATPase), golgi network (gp 26/27) and ER
(calreticulin) and FAT/CD36 is shown for WT MEFs (A) and cav-1 KO MEFs
(B). While FAT/CD36 is present in plasma membrane fractions of WT MEFs, it
is completely absent from plasma membrane fractions of cav-1 KO MEFs.
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Translocation of LCFAs across the plasma membrane is
achieved by a concert of co-existing mechanisms. A number of
recent studies in cell lines and caveolin-1 knockout mice have
suggested that lipid rafts/caveolae and their marker protein, ca-
veolin-1, may play a crucial role in this process [4,5,7,15,29,30].
For the first time, the present study provides functional and mo-
lecular genetic evidence that caveolin-1 targets FAT/CD36 to
plasma membrane caveolae where it is necessary for proper sta-
bilization of FAT/CD36 at the cell surface. In the absence of
caveolin-1, FAT/CD36 is retained in an intracellular pool that
cofractionates with elements of the Golgi network. Expression of
caveolin-1 in cav-1 KO cells is sufficient to redirect FAT/CD36 to
the cell surface. The functional significance of this finding is
underlined by the fact that the reduced [3H]oleate uptake of cav-1
KO MEFs was reversed by caveolin-1 re-expression.
These data may shed a new light on the pathogenesis of
adipose tissue atrophy and elevated serum levels of free fatty acids
observed in cav-1 KO mice (19). Cohen et al. [31] proposed that
these phenotypes might be due to reduced plasma membrane
expression of the insulin receptor resulting in enhanced lipolysis
and diminished lipogenesis. However, there is conflicting data
concerning the effects of caveolin on insulin receptor expression
and function [32,33]. Our results suggest that FAT/CD36 defi-
ciency at the cell surface might, at least in part, contribute to the
metabolic changes observed in cav-1KOmice. Interestingly, FAT/
CD36 knockout mice resemble cav-1 null KO mice in that they
Fig. 5. Recombinant expression of caveolin-1 rescues plasma membrane
caveolae and FAT/CD36 expression. (A) Protein expression of endogenous
caveolin-1 in WTMEFs and KOMEFs and expression of recombinant caveolin-
1-GFP in cav-1 KO MEFs, as assessed by Western Blot with caveolin-1
antibody. While endogenous caveolin-1 can be detected as a 22 kDa protein in
WT MEFs, after transient expression of caveolin-1 in KO MEFs (rCav-1)
caveolin-1-GFP can be identified as a 45 kDa protein. A total of 50 µg of protein
was applied per lane. (B) Electron micrographs of the plasma membrane of
MEFs. Cav-1 KO MEFs are devoid of caveolae structures. Re-expression of
caveolin-1 allows re-formation of caveolae invaginations in the plasma
membrane (arrows), as observed in WT MEFs. Scale bar, 500 nm. (C)
Membrane fractionation of cav-1 KO MEFs 48 h after adenovirus mediated
expression of recombinant caveolin-1 (rCav-1) shows a shift of FAT/CD36
localization to the plasma membrane. In contrast, mock infection with an
adenovirus encoding YFP-GL-GPI had no effect on FAT/CD36 localization in
cav-1 KO MEFs.
Fig. 6. Effects of SSO and caveolin-1 deficiency on [3H]oleate uptake in MEFs.
Pretreatment with SSO (400 μM for 30 min at 37 °C), a selective inhibitor of
FAT/CD36 function, inhibited oleate uptake over 20 s inWTMEFs by 41.1%. In
cav-1 KO MEFs, oleate uptake was reduced by 61.6% compared to WT MEFs.
Pretreatment with SSO had no relevant effect on oleate uptake in cav-1 KO
MEFs. Re-expression of caveolin-1 in cav-1 KO cells (rCav-1) rescued fatty
acid uptake close to the levels of WT MEFs. In rCav-1 cells, pretreatment with
SSO inhibited oleate uptake by almost 40%, although this was not statistically
significant (P=0.07). Values are means ± SD of five independent experiments.
*Pb0.05 for untreated vs. SSO-treated WT MEFs; **Pb0.05 for Cav1 KO vs.
WT MEFs; ***Pb0.05 for rCav-1 vs. cav-1 KO MEFs.
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oleate in isolated adipocytes [3]. However, these knockout mice
differ substantially on some other parameters. Most importantly,
insulin resistance or adipose tissue atrophy have not been observed
in FAT/CD36 deficient mice. Therefore, malfunction of FAT/
CD36 does not fully explain the phenotype of cav-1 KO mice.
An important property of caveolae is that they include and
exclude proteins to a various extent thus achieving a spatial segre-
gation of membrane processes. We and others have previously
reported that FAT/CD36 is enriched in lipid rafts of adipocytes
[4,5,34]. However, contradictory results as to whether FAT/CD36
is present in caveolar rafts or not have been reported. Based on
confocal fluorescence microscopy studies, Zeng et al. [21] sug-
gested that inCHOcells FAT/CD36 is localized in lipid rafts but not
in caveolae. In contrast, Souto and coworkers [34] immunoisolated
caveolae from adipocytes and found FAT/CD36 copurified with
caveolin-1 and subsequently confirmed these findings by electron
microscopical analysis. Frank and coworkers [35] reported that in
Cos7 cells FAT/CD36 was targeted to the plasma membrane only
when cotransfected with caveolin-1. In the absence of caveolin-1,
FAT/CD36 was retained intracellularly in a perinuclear Golgi-like
compartment, as assessed by immunocytochemistry [35]. Finally,
the data from Uittenbogaard et al. [36] show that in human micro-
vascular endothelial cells, CD36 and caveolin-1 co-precipitate
together. Our data show that the expression of FAT/CD36 on the
plasma membrane and in part the uptake of oleate depend on the
presence of caveolin-1. In contrast to the studies by Uittenbogaard
et al. [36] in endothelial cells, we found that caveolin-1 and FAT/
CD36 did not precipitate together in MEFs (data not shown),
suggesting that FAT/CD36 does not directly interact with the scaf-
folding domain of caveolin-1, which is a known binding region for
different proteins within caveolae [37,38]. The mechanism by
which caveolin-1 stabilizes FAT/CD36 within plasma membrane
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with a very short cytoplasmic tail comprising 5–8 amino residues.
Souto and colleagues [34] suggested that oligomerized caveolin
covers the cytoplasmic surface of caveolae and therefore only
membrane proteins with small cytoplasmic domains would have
free access to caveolae, whereas proteins with large cytoplasmic
domains would be excluded by steric limitations.
Little is known about the regulation of FAT/CD36 function,
but in muscle cells, several lines of evidence point toward a
translocation mechanism for increasing LCFA uptake by FAT/
CD36 [39–41]. Muscle cells express a specific type of caveolin,
caveolin-3, which might play a similar role for FAT/CD36
translocation as caveolin-1 in MEFs. Future investigations will
address the question if caveolin-3 might be responsible for
translocation of FAT/CD36 to muscle cell plasma membranes.
We propose a model in which FAT/CD36 recycles from
intracellular non-DRM pools to caveolae at the plasma
membrane. Caveolin-1 may control FAT/CD36 surface avail-
ability and thereby indirectly regulate fatty acid uptake. After
FAT/CD36 mediated binding of LCFAs at the outer leaflet of the
plasma membrane, LCFAs translocate through the membrane
bilayer. Based on previous reports [7,16,17], it is conceivable
that LCFAs translocating to the inner leaflet of adipocyte plasma
membranes may be bound by caveolin-1 that might serve as an
intracellular shuttle trafficking LCFAs to lipid droplets. This issue
needs to be addressed in further studies.
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